Clean Biologics, an international group providing services to the biopharmaceutical industry, appointed Laurent Claisse as chief executive officer. 

Claisse succeeds Joseph Jammal, who served for five years and strengthened group activities, including the operational framework of its subsidiary Clean Cells. Under Jammal’s tenure, Clean Biologics advanced its standing as a leading European expert in quality control services for developers of biotherapies.

Reflecting on his tenure, former CEO Joseph Jammal stated: “I am proud of the impactful transformations we have achieved at Clean Biologics. Laurent’s appointment marks an exciting new chapter focused on extending our commercial and strategic reach, particularly in the U.S.”

Claisse comes to Clean Biologics with international leadership experience, notably in North America, where the group is looking to expand further. He joins Clean Biologics from Sartorius, where he served as senior vice-president of operations. Before that, he held several senior executive roles at Danaher companies, including Pall Corporation and Molecular Devices.

With this appointment, Clean Biologics aims to accelerate its market expansion, especially in the U.S., where the company recently acquired Karyologic, based in North Carolina.

This CEO appointment underscores Clean Biologics’ strategic pivot towards further fine-tuning its commercial approach, positioning the company for enhanced international growth with a stronger foothold in the promising US market for the development of biotherapies.